Asia Pacific Insomnia Companies

Japanese pharmaceutical company Eisai announced in October 2023 that it has received approval in China for its insomnia drug Dayvona (lemborexant). This is a significant development as China is the largest market for insomnia treatments in the Asia Pacific region.

Indian sleep tech startup Hush has raised $10 million in a Series A funding round in January 2024. The company plans to use the funds to expand its sleep apnea and insomnia management platform across Asia.

Australian digital therapeutics company Sleep Health has partnered with Bupa Global to offer its sleep program to Bupa's members in Asia. This partnership will provide access to evidence-based sleep management tools to a wider population in the region.

List of Asia Pacific Insomnia Key Companies in the Market

• Takeda Pharmaceutical Company (Japan)


• Pfizer Inc. (US)


• Eisai


• (Japan)


• Merck & Co Inc (US)


• Sanofi (France)


• GlaxoSmithKline Plc. (UK)


• Meda Consumer Healthcare Inc (US)


• Care Fusion Corporation (US)


• Pernix Therapeutics (US)


• Purdue Pharma L.P. (US)


• Consumer Healthcare Inc. (Canada)


• Dainippon Sumitomo (Japan)


• ECR Pharmaceuticals (US)


• Johnson & Johnson (US)


• Astellas (UK)


• Biocodex S A (France)


• Neurim (Switzerland)


• Flynn Pharma (UK)